Business Context and Reporting Period
This Form 8-K Current Report was filed by vTv Therapeutics Inc. on December 27, 2018. The report discloses a specific corporate event regarding the unregistered sale of equity securities that occurred on the same date.
Key Financial Metrics
The filing details a capital raise transaction but does not provide comprehensive financial statements such as revenue, profit, cash flow, or debt levels.
- Capital Raised: $1.5 million
- Shares Issued: 815,217 shares of Class A common stock
- Price Per Share: $1.84
- Investor: MacAndrews & Forbes Group LLC
Material Changes
The material change reported is the execution of a definitive agreement under the "December 2018 Letter Agreement" dated December 11, 2018. The Company exercised its right to require the Investor to purchase the aforementioned shares, resulting in an immediate infusion of $1.5 million in cash.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure that the transaction details are qualified by reference to the December 2018 Letter Agreement. No unusual items or contingencies are described in this specific report.
Investor Verification Checklist
- Verify the terms of the December 2018 Letter Agreement filed as an exhibit to the Company's 2018 Form 10-K.
- Confirm the total outstanding share count post-transaction to assess dilution impact.
- Review the Company's cash position and burn rate in the most recent 10-K or 10-Q to understand the liquidity impact of the $1.5 million raise.
- Check for any subsequent filings regarding the use of proceeds from this transaction.